Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 197Azacitidine 143Cyclophosphamide 136fludarabine phosphate 112fludarabine 97Busulfan 96venetoclax 95Mycophenolic Acid 82Whole-Body Irradiation 81Tacrolimus 78Peripheral Blood Stem Cell Transplantation 78Decitabine 62Filgrastim 56Granulocyte Colony-Stimulating Factor 54Cyclosporine 53Melphalan 52Methotrexate 51Idarubicin 51Daunorubicin 49Antilymphocyte Serum 47Clofarabine 43Etoposide 41Thiotepa 35Gemtuzumab 34Mitoxantrone 32Stem Cell Transplantation 31CPX-351 27Specimen Handling 25Radiotherapy 25thymoglobulin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Acute × eprenetapopt × Clear all
NCT03931291 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Aprea Therapeutics

Phase 2 Completed
33 enrolled 7 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡